

Mira Tschorn | Stella Linnea Kuhlmann | Nina Rieckmann | Katja Beer | Laura Grosse | Volker Arolt | Johannes Waltenberger | Wilhelm Haverkamp | Jacqueline Müller-Nordhorn | Rainer Hellweg | Andreas Ströhle

Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease

Suggested citation referring to the original publication:

Acta Neuropsychiatrica 33 (2020) 1, pp. 22 - 30

DOI <https://doi.org/10.1017/neu.2020.31>

ISSN 1601-5215

Journal article | Version of record

Secondary publication archived on the Publication Server of the University of Potsdam:

Zweitveröffentlichungen der Universität Potsdam : Humanwissenschaftliche Reihe 850

ISSN: 1866-8364

<https://nbn-resolving.org/urn:nbn:de:kobv:517-opus4-557315>

DOI: <https://doi.org/10.25932/publishup-55731>

Terms of use:

This work is licensed under a Creative Commons License. This does not apply to quoted content from other authors. To view a copy of this license visit <https://creativecommons.org/licenses/by/4.0/>.

Original Article

Cite this article: Tschorn M, Kuhlmann SL, Rieckmann N, Beer K, Grosse L, Arolt V, Waltenberger J, Haverkamp W, Müller-Nordhorn J, Hellweg R, and Ströhle A. (2021) Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease. *Acta Neuropsychiatrica* **33**:22–30. doi: [10.1017/neu.2020.31](https://doi.org/10.1017/neu.2020.31)

Received: 5 February 2020
 Revised: 2 September 2020
 Accepted: 14 September 2020
 First published online: 24 September 2020

Key words:
 depression; BDNF; coronary heart disease; heart failure; somatic comorbidity; acute coronary syndrome


Author for correspondence:
 Mira Tschorn, Email: mira.tschorn@charite.de

*Both authors contributed equally

© Scandinavian College of Neuropsychopharmacology 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.



Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease

Mira Tschorn^{1,2} , Stella Linnea Kuhlmann^{3,4}, Nina Rieckmann³, Katja Beer¹, Laura Grosse^{5,6}, Volker Arolt⁵, Johannes Waltenberger^{7,8}, Wilhelm Haverkamp⁹, Jacqueline Müller-Nordhorn³, Rainer Hellweg^{1,*} and Andreas Ströhle^{1,*}

¹Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health, Berlin, Germany; ²Social and Preventive Medicine, University of Potsdam, Am Neuen Palais 10, 14469 Potsdam, Germany; ³Institute of Public Health, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health, Berlin, Germany; ⁴Division of Emergency and Acute Medicine (CVK, CCM), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health, Berlin, Germany; ⁵Department of Psychiatry and Psychotherapy, University Hospital Münster, Münster, Germany; ⁶Intercultural Business Psychology, Hamm-Lippstadt University of Applied Sciences, Hamm, Germany; ⁷Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany; ⁸Department of Internal Medicine I, SRH Central Hospital Suhl, Suhl, Germany and ⁹Department of Internal Medicine and Cardiology, Charité – Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health, Berlin, Germany

Abstract

Objective: Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). **Methods:** The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. **Results:** Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients ($p = 0.04$), this was not statistically significant after controlling for confounders ($p = 0.15$). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations ($p = 0.08$, $p = 0.06$, respectively). BDNF was reduced in patients with CHF ($p = 0.02$). There was no covariate-adjusted, significant association between BDNF and ACS. **Conclusion:** Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.

Significant outcomes

- Patients with coronary heart disease (CHD) and comorbid congestive heart failure (CHF) show significantly lower levels of brain-derived neurotrophic factor (BDNF) than patients with CHD without comorbid CHF, also after controlling for potential confounders and depression.
- BDNF was significantly reduced in depressed patients with CHD compared to non-depressed patients with CHD, but this association was not significant after controlling for somatic comorbidity, platelet count, smoking status, sex, age and antidepressant treatment. We therefore suggest to carefully report and control for possible relevant confounders while investigating BDNF and depression in future research.

Limitations

- The relatively small sample size ($N = 225$), the cross-sectional study design and limited generalisability to patients with CHD limit the results of the present study.

Introduction

Coronary heart disease (CHD) and depression are leading contributors to the global burden of disease (GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, 2018; Rehm & Shield, 2019). The two diseases are marked by a high comorbidity (Rudisch & Nemeroff, 2003), a worse medical prognosis for patients suffering from both diseases (Meijer *et al.*, 2011), and a dose–effect relationship between severity of depression and cardiac prognosis, such as long-term cardiac mortality (Lespérance *et al.*, 2002; Whooley *et al.*, 2008). Prevalence rates for major depression in patients with CHD vary from 10 to 27%, depending on the type of depression assessment and CHD severity (Rudisch & Nemeroff, 2003). A similar picture exists for the association between congestive heart failure (CHF) and depression (Mbakwem *et al.*, 2016). Inflammation, the autonomic nervous system, the hypothalamic–pituitary–adrenal axis, endothelial dysfunction, platelet function, serotonin and polyunsaturated fatty acids have been suggested as biological factors linking depression and cardiovascular disorders (CVDs) (de Jonge *et al.*, 2010). One biological marker particularly associated with depression and CHD is brain-derived neurotrophic factor (BDNF). BDNF is a neurotrophin that is crucial for synaptic function and neuronal plasticity (Allen & Dawbarn, 2006). Blood BDNF concentrations are known to reflect concentrations of BDNF in the brain (Sartorius *et al.*, 2009). In the hippocampus, BDNF plays an important role in learning and memory function (Allen & Dawbarn, 2006) and it has repeatedly been linked to depression (Brunoni *et al.*, 2008; Bocchio-Chiavetto *et al.*, 2010; Zhang *et al.*, 2011; Molendijk *et al.*, 2014). Meta-analyses have demonstrated an increase in BDNF after antidepressant treatment (Brunoni *et al.*, 2008). Therefore, current research assumes that synaptic and neuroplasticity have an important role of in the development and treatment of depression (Brunoni *et al.*, 2008) via a stress-induced reduction in expression of BDNF in the limbic regions that control mood (Duman & Monteggia, 2006).

Recent research has also attributed BDNF an important role in the cardiovascular system. BDNF is synthesised and released in non-neuronal cells; it has been shown to be involved in cardiovascular development (Caporali & Emanuelli, 2009) and connected to several important cardiac processes, such as coronary vessel development, angiogenesis, survival of cardiomyocytes, vascular growth, vascular smooth muscle cell migration and revascularisation (Kermani *et al.*, 2005; Pius-Sadowska & Machaliński, 2017). Reduced BDNF concentrations have been associated with cardiovascular-related mortality, future coronary events in patients with angina pectoris, risk factors for cardiovascular dysfunction and acute coronary syndrome (ACS) (Manni *et al.*, 2005; Jiang *et al.*, 2011). Furthermore, BDNF seems to play a specific role in cardiac injury (Donovan *et al.*, 1995; Okada *et al.*, 2012). Ejiri *et al.* proposed that BDNF not only has a cardioprotective effect but also contributes to atherogenesis and plaque instability via BDNF-induced oxidative stress (Ejiri *et al.*, 2005).

A role of BDNF in physiological processes has recently also been shown outside of neurological or cardiovascular mechanisms (Wang *et al.*, 2016; Chen *et al.*, 2016). Moreover, there is early evidence of sex-specific associations of BDNF and physiological outcomes (Wang *et al.*, 2016; Schmalhofer *et al.*, 2019).

There is growing evidence linking BDNF to CHF: CHF and the severity of its symptoms have been shown to be associated with decreased BDNF concentrations (Takashio *et al.*, 2015; Kadowaki *et al.*, 2016). Moreover, it has been shown that BDNF concentrations have a predictive value regarding future

clinical outcomes in patients with CHF (Fukushima *et al.*, 2015; Kadowaki *et al.*, 2016).

However, cause and effect of BDNF and cardiovascular mechanisms are currently still unclear (Ejiri *et al.*, 2005; Hashimoto, 2013; Bahls *et al.*, 2019).

A number of studies have examined BDNF's role in the relationship between CVD and depression (Bozzini *et al.*, 2009; Liu *et al.*, 2014; Kang *et al.*, 2016; Kuhlmann *et al.*, 2017; Han *et al.*, 2019). It has been demonstrated that BDNF-related Val66Met polymorphism is involved in both depression and CHD. It is suggested that the met allele associated with low BDNF secretion plays a role in CHD pathogenesis and is associated with an elevated risk of depression in patients with ACS. Moreover, met allele carriers exhibited higher remission rates after antidepressant treatment and were more vulnerable to persistent depression in longitudinally designed studies (Bozzini *et al.*, 2009; Liu *et al.*, 2014; Kang *et al.*, 2016). In line with this finding, lower serum concentrations of BDNF appear to be associated with the persistence but not the incidence of depressive symptoms (Kuhlmann *et al.*, 2017). The only other study to investigate BDNF blood concentration's role in the link between a cardiovascular disease (CHF) and depression failed to find an association between BDNF concentrations and depressive symptoms (Fukushima *et al.*, 2015). To date, BDNF serum concentrations in patients with CHD have not been investigated in the context of depressive symptoms.

Due to the extensive physical and mental pathologies that have been linked to BDNF, such as inflammation, cardiovascular pathologies and neurodegenerative diseases such as Alzheimer's disease (Allen & Dawbarn, 2006; Pius-Sadowska & Machaliński, 2017), accurately controlling for a wide range of possible physical and psychological confounders, when investigating the link between BDNF and somatic disease or BDNF and depression, appears to be important. The studies investigating links between BDNF and CVD were mainly controlled for age, sex and some physical parameters, but most of them did not control for the medical comorbidity burden. Previous studies on patients with CHD found differential associations for somatic versus cognitive-affective depressive symptoms: cognitive-affective symptoms were associated with the clinical recognition of a depressive disorder in patients with acute myocardial infarction (MI), while somatic symptoms were not. Somatic symptoms were more consistent predictors of mortality and rehospitalisation as long-term outcomes than cognitive-affective depressive symptoms (de Jonge *et al.*, 2007; Smolderen *et al.*, 2009).

The aim of the present study was to investigate whether depression and somatic comorbidities are independently linked to levels of BDNF, in hospitalised patients with CHD. Specifically, we analysed the relationships between BDNF and overall depressive symptom level, overall somatic comorbidity burden, CHF and occurrence of an ACS, while controlling for pre-specified confounders

Methods

Study design and blood collection

In total, 322 hospitalised patients with CHD were recruited from two study sites (cardiac units at the Charité – Universitätsmedizin Berlin and University Hospital Münster) in Germany between December 2012 and November 2015. Patients with a documented CHD (diagnosis in the medical chart), sufficient language skills and no severe cognitive impairments or terminal disease were eligible for inclusion in this observational, cross-sectional study.

A member of the study team drew blood (8.5 ml) from hospitalised patients who had provided written and informed consent; this was allowed to clot for 30–60 min and centrifuged at 3500 rpm for 15 min at 4°C. The serum was removed and stored at –20°C until the BDNF concentrations were determined. Data from 97 patients were excluded from the analyses for various reasons [withdrawn consent, suspected CHD not confirmed by diagnostic process during treatment, cognitive impairment which was not documented pre-inclusion, no completed baseline questionnaire, clotting time of less than 30 min and unreliable BDNF measurement (<0.5 ng/ml)]. A detailed flow chart of the study has been reported previously (Kuhlmann *et al.*, 2017).

BDNF determination

The serum BDNF concentrations were measured using highly sensitive and specific, fluorometric, two-site enzyme-linked immunosorbent assays (ELISA), according to the manufacturer's instructions (Promega Inc, Mannheim, Germany) but modified for a fluorometric technique: primary anti-BDNF monoclonal antibody (Promega Inc, Cat#: G7610), anti-human-BDNF polyclonal antibody (Promega Inc, Cat#: G1641) and goat anti-chicken-IgY-alkaline phosphatase polyclonal secondary antibody (Abcam, Cat#: ab97142) were used before the enzyme reaction was started and stopped after one night of incubation in a dark, moist chamber at room temperature. The procedure has previously been described in further detail (Hellweg *et al.*, 2003; Ziegenhorn *et al.*, 2007).

Assessment of sociodemographic variables, depressive symptoms and medical parameters

Depressive symptoms and demographic characteristics were assessed using a self-rating questionnaire that was completed either during hospitalisation or within 3 weeks after discharge. Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-9), a standard instrument which is widely used to screen for clinical depression and to measure depression severity (Kroenke *et al.*, 2001). Medical charts were reviewed to collect relevant medical information, including the presence of an ACS (unstable angina pectoris or MI), CHF, antidepressant medication at hospital admission, body mass index (BMI), hypertension, diabetes, dyslipidemia, left ventricular ejection fraction (LVEF), history of MI, history of revascularisation (percutaneous coronary intervention or bypass operation), length of hospital stay and platelet count. The latter was assessed to account for the links between platelet alterations and both BDNF and depression (Ziegenhorn *et al.*, 2007; Serra-Millàs, 2016). Furthermore, variables were extracted from medical charts for the Charlson Comorbidity Index [CCI, (Charlson *et al.*, 1987)]. The CCI was used in two variations: the CCI according to the original publication and a modified version without CHF and MI, in order to control for comorbid somatic diseases other than cardiac diseases.

Statistical analyses

Regression-based multiple imputation was used to manage missing data and predictors were selected based on associated variables (Holmes *et al.*, 2003; Siew *et al.*, 2013; Biering *et al.*, 2015). The detailed procedure has been described previously (Kuhlmann *et al.*, 2017). The PHQ-9 depression scale was summed to give a total score and also divided into two subscales (cognitive-affective and somatic), in line with previous studies in cardiac patients (de

Jonge *et al.*, 2007; Smolderen *et al.*, 2009). In addition, patients were grouped into those with 'elevated depressive symptoms' versus 'non-elevated depressive symptoms', using a PHQ-9 score of 7 as the cut-point. This cut-point was chosen because it had shown the best trade-off between sensitivity and specificity for a clinical depression diagnosis in a larger sample of hospitalised patients with CHD who were recruited from the same study sites (Tschorn *et al.*, 2019).

To compare depressed versus non-depressed patients concerning relevant sociodemographic and clinical variables, chi-square statistics were conducted for nominal variables (sex, smoking status, use of antidepressants, ACS, CHF, hypertension, diabetes, dyslipidemia, MI and revascularisation), *t*-tests were used for continuous variables (age, platelets, PHQ-9, serum BDNF, BMI and LVEF), and Mann–Whitney *U*-tests were used to compare medians (modified CCI and length of hospital stay). Correlation analyses were used to assess associations between continuous covariates (age and platelet count), and BDNF and *t*-tests were used to analyse dichotomous covariates (sex, smoking status and use of antidepressants) and BDNF levels. Linear regression analyses were computed to investigate the relationships between BDNF and PHQ-9, PHQ-9 subscales, and somatic comorbidity (CCI). Multiple regression analyses were used to control for possible confounders. We used logistic regression models to analyse the relationship between PHQ-9 groups (depressed vs. non-depressed) and BDNF concentrations. Likewise, two further logistic regression models were used to analyse the relationships of ACS and CHF with BDNF. All the analyses were conducted using IBM SPSS version 25. All the reported *p*-values are two-sided and were considered statistically significant at <0.05.

Specification of confounders

Variables were considered to be confounders if a link to both the currently analysed variables was found repeatedly in the relevant literature (e.g. BDNF and depression, ACS/CHF and BDNF, somatic comorbidity and BDNF). All the analyses investigating BDNF and depression included age, sex, smoking status, use of antidepressants, platelet count and three markers of somatic comorbidity as possible confounders: ACS, CHF and the modified CCI. The analyses to investigate BDNF and CCI included age, sex, platelet count, PHQ-9 sum score and smoking status as confounders. All the analyses investigating BDNF and CHF or ACS were adjusted for age, sex, platelet count, PHQ-9 sum score, smoking status and modified CCI. Confounder selection and adjustment is based on the definition of BDNF as the exposure variable for depression as the outcome variable. When investigating associations of CHF, ACS and CCI with BDNF, we defined BDNF as the exposure variable of CHF, ACS, and CCI as outcome variables. Collinearity diagnostics did not reveal any multicollinearity in the adjusted regression models.

Results

The sociodemographic and clinical characteristics of the overall sample ($N = 225$), as well as the depression groups, are shown in Table 1.

BDNF concentrations and depressive symptom severity

The link between BDNF concentrations and depressive symptoms (PHQ-9) did not reach significance ($\beta = -0.114$, $CI = -0.246$ – 0.018 , $p = 0.09$, Table 2). A statistical trend disappeared when possible confounders were controlled for ($\beta = -0.085$, $CI = -0.224$ – 0.054 , $p = 0.23$). This relationship was also examined by

Table 1. Sample characteristics

	Overall sample <i>n</i> = 225	PHQ-9 <7 <i>n</i> = 131 (58%)	PHQ-9 ≥7 <i>n</i> = 94 (42%)	<i>p</i>
Age, <i>M</i> ± <i>SD</i> /range	64.3 ± 10.8/53	65.3 ± 10.8/53	62.8 ± 10.6/38	0.09
Female, <i>n</i> (%)	46 (20.4)	30 (22.9)	16 (17)	0.28
Smoking, <i>n</i> (%)	66 (29.3)	36 (27.5)	30 (31.9)	0.47
Platelet count, <i>M</i> ± <i>SD</i>	230.9 ± 84.5	237.9 ± 95.2	221.2 ± 66.3	0.14
Current use of antidepressants, <i>n</i> (%)	11 (4.9)	3 (2.3)	8 (8.5)	0.03
PHQ-9, <i>M</i> ± <i>SD</i>	6.7 ± 5.1	3.3 ± 2	11.5 ± 4	0.00
Serum BDNF in ng/ml, <i>M</i> ± <i>SD</i>	3.04 ± 1.12	3.17 ± 1.14	2.85 ± 1.08	0.03
ACS, <i>n</i> (%)	93 (41.3)	58 (44.3)	35 (37.2)	0.29
CHF, <i>n</i> (%)	77 (34.2)	36 (27.5)	41 (43.6)	0.01
Modified CCI, median ± <i>SD</i>	0 ± 1.2	0 ± 1.2	1 ± 1.2	0.03
BMI, <i>M</i> ± <i>SD</i>	28.2 ± 5	27.5 ± 4.9	29.2 ± 5.1	0.01
Hypertension, <i>n</i> (%)	202 (89.8)	114 (87)	88 (93.6)	0.11
Diabetes, <i>n</i> (%)	57 (25.3)	37 (28.2)	20 (21.3)	0.24
Dyslipidemia, <i>n</i> (%)	170 (75.6)	96 (73.3)	74 (78.7)	0.35
History of MI, <i>n</i> (%)	93 (41.3)	50 (38.2)	43 (45.7)	0.26
History of revascularisation, <i>n</i> (%)	148 (65.8)	77 (58.8)	71 (75.5)	0.01
LVEF, <i>M</i> ± <i>SD</i>	47.8 ± 14.1	48.7 ± 12.4	46.5 ± 16.1	0.26
Length of hospital stay median ± <i>SD</i> /range in days*	4 ± 6.2/49	4 ± 5.4/45	3 ± 7.3/49	0.27

PHQ-9, Patient Health Questionnaire-9; ACS, acute coronary syndrome; CHF, congestive heart failure; CCI, Charlson Comorbidity Index; BDNF, brain-derived neurotrophic factor; BMI, body mass index; MI, myocardial infarction; LVEF, left ventricular ejection fraction.

Chi-square statistics were used to compare nominal variables, *t*-tests were used to compare continuous variables and Mann-Whitney *U*-tests were used to compare medians.

*Length of hospital stay was reported for *n* = 215 patients.

Significant *p* values (<0.05) are highlighted in bold.

comparing depressed and non-depressed patients with CHD, grouped by the PHQ-9 cut-point of 7 via logistic regression, which revealed a statistically significant difference; BDNF concentrations in non-depressed patients were higher than in depressed patients [2.85 ng/ml vs. 3.17 ng/ml, odds ratio (OR) = 0.768, CI = 0.601–0.983, *p* = 0.04]. This difference was no longer statistically significant after adjustment for confounders (OR = 0.820, CI = 0.624–1.078, *p* = 0.015).

BDNF concentrations and PHQ-9 cognitive-affective and somatic subscales

There was no statistically significant correlation between the PHQ-9 somatic subscale and BDNF (β = -0.090, CI = -0.221–0.041, *p* = 0.18, Table 2). The correlation between the PHQ-9 cognitive-affective subscale and BDNF closely missed significance (β = -0.116, CI = -0.248–0.016, *p* = 0.08). A statistical trend for a negative correlation with BDNF concentrations was also found after controlling for confounders (β = -0.114, CI = -0.262–0.016, *p* = 0.08).

BDNF concentrations and CCI

Lower BDNF concentrations were significantly associated with a higher burden of somatic comorbidity (CCI, β = -0.149, CI = -0.280–0.018, *p* = 0.03, Table 3). This link narrowly missed significance after controlling for confounders (β = -0.123, CI = -0.254–0.006, *p* = 0.06). Furthermore, lower BDNF concentrations were associated with higher scores for non-cardiac comorbidity burden (modified CCI, β = -0.131, CI = -0.262–0.000, *p* = 0.05). This

association was no longer statistically significant after controlling for confounders (β = -0.103, CI = -0.236–0.030, *p* = 0.13).

Sex-stratified analyses of BDNF concentrations and CCI

Overall somatic comorbidity burden was significantly associated with BDNF concentrations in women (CCI, β = -0.355, CI = -0.640–0.079, *p* = 0.02), also after controlling for confounders (β = -0.360, CI = -0.653–0.067, *p* = 0.02). There was no association between overall somatic comorbidity and BDNF concentrations in men (β = -0.082, CI = -0.280–0.066, *p* = 0.28). Likewise, the modified (non-cardiac) somatic comorbidity burden was significantly associated with BDNF concentrations in women (β = -0.353, CI = -0.638–0.068, *p* = 0.02), also after confounder adjustment (β = -0.343, CI = -0.642–0.042, *p* = 0.03). No association between non-cardiac somatic comorbidity and BDNF was found in men (β = -0.034, CI = -0.183–0.115, *p* = 0.66).

BDNF concentrations and CHF

BDNF concentrations were lower in patients with CHF than in patients without it (2.73 ng/ml vs. 3.20 ng/ml, OR = 0.667, CI = 0.510–0.873, *p* = 0.00). This difference remained constant after adjusting for possible confounders (OR = 0.702, CI = 0.528–0.934, *p* = 0.02).

BDNF concentrations and ACS

BDNF concentrations were higher in patients with ACS, compared to CHD patients without ACS (3.23 ng/ml vs. 2.90 ng/ml,

Table 2. Associations between BDNF, covariates and depression

BDNF and covariates								
BDNF								
		<i>N</i>	Correlation		<i>p</i>			
Age		225	$r = -0.15$		0.02			
Platelet count		225	$r = 0.25$		0.00			
			Mean (ng/ml)	SD (ng/ml)				
Sex	Female	46	3.17	1.16				
	Male	179	3.01	1.11				
Smoking	Smoking	66	3.20	1.25				
	Non-smoking	159	2.97	1.06				
Current use of antidepressants	Antidepressants	11	3.12	1.15				
	No antidepressants	214	3.04	1.12				
BDNF and depression: unadjusted and adjusted regression models								
			Unadjusted			Covariate-adjusted		
			β	95% CI	<i>p</i>	β	95% CI	<i>p</i>
PHQ-9		225	-0.114	-0.246-0.018	0.09	-0.085	-0.224-0.054	0.23
PHQ-9 COG		225	-0.116	-0.248-0.016	0.08	-0.114	-0.262-0.016	0.08
PHQ-9 SOM		225	-0.090	-0.221-0.041	0.18	-0.029	-0.172-0.110	0.66
			OR	95% CI	<i>p</i>	OR	95% CI	<i>p</i>
PHQ-9								
Cut-point 7								
	≥7: depressed	94	0.768	0.601-0.983	0.04	0.820	0.624-1.078	0.15
	<7: non-depressed	131						

BDNF, brain-derived neurotrophic factor; SD, standard deviation; 95% CI, 95% confidence interval; PHQ-9, Patient Health Questionnaire-9; SOM, somatic depressive symptoms; COG, cognitive-affective depressive symptoms; OR, odds ratio. Significant *p* values (<0.05) are highlighted in bold.

Table 3. Relationships of BDNF with somatic comorbidity, congestive heart failure and acute coronary syndrome (unadjusted and adjusted regression models)

BDNF								
		<i>N</i>	Unadjusted			Covariate-adjusted		
			β	95% CI	<i>p</i>	β	95% CI	<i>p</i>
CCI		225	-0.149	-0.280-0.018	0.03	-0.123	-0.254-0.006	0.06
CCI female		46	-0.355	-0.640-0.070	0.02	-0.360	-0.653-0.067	0.02
CCI male		179	-0.082	-0.230-0.066	0.28	-0.057	-0.205-0.090	0.44
Modified CCI		225	-0.131	-0.262-0.000	0.05	-0.103	-0.236-0.030	0.13
Mod. CCI female		46	-0.353	-0.638-0.068	0.02	-0.343	-0.642-0.042	0.03
Mod. CCI male		179	-0.057	-0.206-0.091	0.45	-0.034	-0.183-0.115	0.66
			OR	95% CI	<i>p</i>	OR	95% CI	<i>p</i>
CHF	CHF no CHF	77148	0.667	0.510-0.873	0.00	0.702	0.528-0.934	0.02
ACS	ACS no ACS	93132	1.304	1.024-1.662	0.03	1.173	0.896-1.535	0.25

BDNF, brain-derived neurotrophic factor; SD, standard deviation; 95% CI, 95% confidence interval; ACS, acute coronary syndrome; CHF, congestive heart failure; CCI, Charlson Comorbidity Index; Mod. CCI, modified CCI (without cardiac conditions); OR, odds ratio. Significant *p* values (<0.05) are highlighted in bold.

OR = 1.304, CI = 1.024-1.662, *p* = 0.03). However, this statistically significant difference disappeared after adjusting for confounders (OR = 1.173, CI = 0.896-1.535, *p* = 0.25).

Discussion

The current study investigated the relationship between depressive symptoms, somatic comorbidity and BDNF concentrations in patients with CHD.

BDNF and depression in patients with CHD

The results of this study show that the association of lower BDNF concentrations with depressive symptoms in patients with CHD no longer exists when adjustments are made for possible confounders. Likewise, a statistical trend towards a linear relationship between depressive symptoms and BDNF concentrations disappears after controlling for possible confounders. While one of two pre-existing investigation of BDNF concentrations and depression in a sample of cardiac patients also found no

association, which might be due to the very small subsample ($n = 4$) of depressed patients (Fukushima *et al.*, 2015), a very recent study found a negative association of BDNF levels and depression scores as well as depression groups (Han *et al.*, 2019). However, Han *et al.* did not report any confounder adjustments. As Molendijk *et al.* (2014) reported studies investigating BDNF concentrations and depression show heterogeneity of outcomes and clinical characteristics, the latter being poorly reported in most studies. The majority of studies investigating BDNF and depression were only controlled for sex or age as possible confounders. Many studies did not control for any possible confounders, although some adjusted for BMI or smoking status. The present study showed particularly that the somatic depressive symptoms in the PHQ-9 depression scale did not show an association with BDNF, once the influence of somatic confounding variables was taken into account, which can be explained by the large overlap of somatic depressive symptoms and CHD symptoms. In contrast, a small link was shown between cognitive-affective depressive symptoms and BDNF concentrations that only narrowly missed statistical significance, also after adjusting for somatic confounders. This association at trend level could yield different results in a larger sample. Our data leave the position of the hypothesis about the role of BDNF in mood control found in the literature unclear (Duman & Monteggia, 2006); however, they do support Molendijk *et al.*'s conclusion that the link between depression and BDNF concentrations is smaller than was initially thought (Molendijk *et al.*, 2014).

Regarding the adjustment for cardiovascular conditions (e.g. ACS or CHF), it is important to point to the fact that the causal direction of the association between cardiovascular conditions and BDNF, especially concerning different disease stages, still remains unclear (Ejiri *et al.*, 2005; Hashimoto, 2013; Bahls *et al.*, 2019). Our models investigating this association cannot account for this uncertainty. Furthermore, including a confounder that is a descendant of the outcome can introduce a statistical bias (Shrier & Platt, 2008). If we assume a unidirectional causal link from BDNF to ACS and CHF (ACS and CHF descendants of BDNF), then controlling for ACS and CHF in the link between BDNF and depression would mean a risk of introducing such a statistical bias. However, an exclusion of these confounders based on this concern did not alter the significance levels of our results.

BDNF and its link to somatic comorbidity, CHF and ACS:

The present study did not provide clear results in our overall sample about a possible association between somatic comorbidity and BDNF concentrations. However, in our sample of patients with CHD, this association appeared to be stronger than the link between depression and BDNF concentrations. However, sex-stratified analyses revealed statistically significant associations for overall somatic comorbidity as well as non-cardiac somatic comorbidity in women, also after adjustment for confounders. Although our female sample only consisted of 46 participants, this finding is in line with associations of BDNF and cardiovascular outcomes only in female participants of a large study investigating both sexes (Schmalhofer *et al.*, 2019). Sex-dependent effects of BDNF are commonly explained by mechanisms involving sex steroids (Carbone & Handa, 2012), but the sex-specific association on BDNF and cardiorespiratory fitness found by Schmalhofer *et al.* was independent of menopause status (Schmalhofer *et al.*, 2019). Therefore, sex-specific effects of BDNF might involve more than sex steroids. Taken together, our results add to the literature

that reports mechanisms involving BDNF beyond neurological and also beyond cardiovascular pathophysiology (Chen *et al.*, 2016; Wang *et al.*, 2016) and that also identified sex-dependent processes (Wang *et al.*, 2016; Schmalhofer *et al.*, 2019). Nevertheless, these results from our small female subsample must be interpreted cautiously and further research is warranted.

The patients with CHD and comorbid CHF showed lower concentrations of BDNF, compared to patients with CHD but without CHF. This finding is in line with the results published by Takashio *et al.* (2015) and Kadowaki *et al.* (2016), who found lower BDNF concentrations in CHF patients, compared to the controls. Since we compared patients with CHD and comorbid CHF and patients with CHD but without comorbid CHF, our results suggest a negative dose-response relationship for cardiovascular dysfunction and BDNF concentrations which occurs independently of depressive symptoms. Recent findings about the link between CHF and BDNF have suggested that an impairment in skeletal muscle BDNF secretion and the skeletal muscle energy metabolism may be the mechanisms explaining lower BDNF levels in CHF patients (Fukushima *et al.*, 2015; Takashio *et al.*, 2015; Kadowaki *et al.*, 2016). On the other hand, Rasmussen *et al.* (2009) showed that three-quarter of BDNF concentrations were produced in the brain and only a minor part of BDNF synthesis was localised in skeletal muscles. Manni *et al.* (2005) found decreased BDNF concentrations in ACS patients, compared to healthy controls. In contrast, our study showed that of the patients with CHD, those with ACS, initially had higher BDNF concentrations than those patients with CHD but without ACS, a finding which did not remain statistically significant after adjusting for confounders. A possible increase in BDNF expression after cardiac injury has been suggested by Okada *et al.* (2012) and Donovan *et al.* (1995). However, this ACS-associated increase in BDNF was no longer apparent in our sample after controlling for possible confounders.

Based on the literature, we hypothesise a causal relationship from BDNF to depression; therefore, we interpret depression as a descendant of BDNF. As described above, adjusting for a descendant of the outcome can introduce a statistical bias (Shrier & Platt, 2008). Since the causal role of BDNF is not conclusively answered and since our main goal was to investigate the relationships of BDNF with three somatic conditions (ACS, CHF and overall somatic comorbidity) independently from depression, we decided to include depression as a confounder nonetheless. However, an exclusion of depression from the set of confounders did not change the results for CHF and ACS. Only for overall comorbidity (CCI), the relationship to BDNF stayed statistically significant also after controlling for confounders ($\beta = -0.138$, $CI = -0.266-0.009$, $p = 0.04$) when depression was removed from the set of confounders, which hints to a link between BDNF and somatic comorbidity which involves a role of depression.

Limitations

The limitations of the present study are a small sample size that was not based on a power analysis considering the high prevalence of CHD and lack of opportunity to not only adjust for platelet count but also for platelet activation, as the potential mechanism between depression and BDNF levels (Serra-Millàs, 2016). Furthermore, the cross-sectional study design and a limited generalisability to patients with CHD must be noted as limitations. Since BDNF levels show a wide range depending on the specific measurement protocols used in different laboratories (Polacchini *et al.*, 2015), no

reference values for serum BDNF exist to allow comparisons of the values generated in different laboratories.

A storage time of more than 12 months can reduce BDNF concentrations in serum samples (Trajkovska *et al.*, 2007). None of our 225 samples were stored for more than 13 months. However, 11 samples were stored for more than 12 months. An exclusion of these 11 samples would alter our result for ACS and the modified CCI (see Table 3): unadjusted regression models showed no association between BDNF and ACS ($OR = 1.236$, $CI = 0.963$ – 1.586 , $p = 0.10$) or BDNF and modified CCI ($\beta = -0.126$, $CI = -0.260$ – 0.009 , $p = 0.07$).

When confounding factors are adjusted for, the specification of covariates always implies causal assumptions that are rarely made explicit. The present study aims to disassemble the associations of BDNF, depression and cardiovascular conditions; therefore, we needed to imply causal assumptions for complex biological mechanisms, although the current literature does not conclusively answer questions about causalities in this field. To further improve the investigation of causalities and the specification of important confounders, the use of directed acyclic graphs (DAGs) and DAG-specific reviews for a certain field of research (e.g. Lewis & Kuerbis, 2016; Williams *et al.*, 2018) appear recommendable in future research.

Conclusion

This data show that severe cardiac disease (as indicated by CHF) is associated with lower BDNF concentrations, independent of potential confounders and depressive symptoms. In our sample of patients with CHD, a link between lower BDNF concentrations and depression groups did not withstand a consideration of possible confounders.

Taken together, the present study found an association between cardiovascular dysfunction and serum BDNF concentrations, while no covariate-adjusted links between depressive symptoms or somatic comorbidity and BDNF concentrations were found.

The findings of the present study support the necessity of considering relevant confounders, especially variables associated with cardiac dysfunction and illness when investigating the link between BDNF and depression. Overall, carefully reporting of clinical characteristics and the development of study designs that aim to minimise the effect of confounding factors might help to clarify the role of BDNF in the pathogenesis of depression.

Acknowledgements. We gratefully acknowledge technical assistance from Silvia Saft. Furthermore, we gratefully thank Victoria Engelmann, Lena Kuner, Julia Brandt and Katharina Warnke for their assistance in recruiting patients and collecting samples.

Authors Contributions. Mira Tschorn: study conception and design, coordination of data acquisition, analysis and interpretation of data, drafting of manuscript, and final approval

Stella Linnea Kuhlmann: acquisition of data, analysis and interpretation of data, critical revision and final approval of the article

Nina Rieckmann: study conception and design, coordination of data acquisition, analysis and interpretation of data, critical revision and final approval of the article

Katja Beer: study conception and design, coordination of data acquisition, analysis data, critical revision and final approval

Laura Grosse: coordination of data acquisition, analysis of data, critical revision and final approval of the article

Volker Arolt: study conception and design, coordination of data acquisition, critical revision and final approval of the article

Johannes Waltenberger: acquisition of data, study conception and design, critical revision and final approval of the article

Wilhelm Haverkamp: acquisition of data, study conception and design, critical revision and final approval of the article

Jacqueline Müller-Nordhorn: study conception and design, critical revision and final approval of the article

Rainer Hellweg: study conception and design, acquisition of data (lab analyses), analysis and interpretation of data, critical revision and final approval of the article

Andreas Ströhle: study conception and design, interpretation of data, critical revision and final approval of the article

Financial support. The current study was an add-on study to the study *Depression Care for Hospitalized Coronary Heart Disease Patients* (CDCare). CDCare was supported by the German Federal Ministry of Education and Research (grant number: 01GY1154). The funder had no role in the study design, data collection and analysis, interpretation of data, preparation of the manuscript, or decision to publish.

Conflict of interest. Volker Arolt received support from the German Federal Ministry of Education and Research, European Union and the Medical Faculty Münster for the submitted work and personal fees from Allergan, Janssen-Cilag, Lundbeck, Otsuka, Servier and Trommsdorff, unconnected with the submitted work.

Johannes Waltenberger reports personal fees and non-financial support from Bayer, Boehringer Ingelheim, Daiichi-Sankyo and Biotronik, as well as personal fees from MSD, Berlin Chemie, Sanofi Aventis and Vifor, unconnected with the submitted work.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

- Allen SJ and Dawbarn D (2006) Clinical relevance of the neurotrophins and their receptors. *Clinical Science* **110**(2), 175–191.
- Bahls M, Könemann S, Markus MR, Wenzel K, Friedrich Z, Nauck M, Völzke H, Steveling A, Janowitz D, Grabe HJ and Felix DMSB (2019) Brain-derived neurotrophic factor is related with adverse cardiac remodeling and high NTproBNP. *Scientific Reports* **9**(1), 1–9.
- Biering K, Hjollund NH and Frydenberg M (2015) Using multiple imputation to deal with missing data and attrition in longitudinal studies with repeated measures of patient-reported outcomes. *Clinical Epidemiology* **7**, 91.
- Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA and Gennarelli M (2010) Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. *The World Journal of Biological Psychiatry* **11**(6), 763–773. <https://doi.org/10.3109/15622971003611319>.
- Bozzini S, Gambelli P, Boiocchi C, Schirinzi S, Falcone R, Buzzi P, Storti C and Falcone C (2009) Coronary artery disease and depression: Possible role of brain-derived neurotrophic factor and serotonin transporter gene polymorphisms. *International Journal of Molecular Medicine* **24**(6), 813–818.
- Brunoni AR, Lopes M and Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. *International Journal of Neuropsychopharmacology* **11**(8), 1169–1180. <https://doi.org/10.1017/S1461145708009309>.
- Caporali A and Emanuelli C (2009) Cardiovascular actions of neurotrophins. *Physiological Reviews* **89**(1), 279–308. <https://doi.org/10.1152/physrev.00007.2008>.
- Carbone DL and Handa RJ (2013) Sex and stress hormone influences on the expression and activity of brain-derived neurotrophic factor. *Neuroscience* **239**, 295–303.
- Charlson ME, Pompei P, Ales KL and MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases* **40**(5), 373–383.

- Chen B, Liang Y, He Z, An Y, Zhao W and Wu J** (2016) Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung cancer proliferation. *Scientific Reports* **6**, 30404.
- de Jonge P, Mangano D and Whooley MA** (2007) Differential association of cognitive and somatic depressive symptoms with heart rate variability in patients with stable coronary heart disease: Findings from the Heart and Soul Study. *Psychosomatic Medicine* **69**(8), 735–739. <https://doi.org/10.1097/PSY.0b013e31815743ca>.
- de Jonge P, Rosmalen JG, Kema IP, Doornbos B, van Melle JP, Pouwer F and Kupper N** (2010) Psychophysiological biomarkers explaining the association between depression and prognosis in coronary artery patients: A critical review of the literature. *Neuroscience & Biobehavioral Reviews* **35**(1), 84–90.
- Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D, Sharif S, Kaplan DR, Tsoulfas P, Parada L, Toran-Allerand CD, Hajjar DP and Hempstead BL** (1995) Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. *American Journal of Pathology* **147**(2), 309–324.
- Duman RS and Monteggia LM** (2006) A neurotrophic model for stress-related mood disorders. *Biological Psychiatry* **59**(12), 1116–1127. <https://doi.org/10.1016/j.biopsych.2006.02.013>.
- Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T, Takahasi M, Ohashi Y, Ichikawa S, Terashima M, Mori T, Awano K, Shinke T, Shite J, Hirata K, Yokozaki H, Kawashima S and Yokoyama M** (2005) Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. *Circulation* **112**(14), 2114–2120. <https://doi.org/10.1161/CIRCULATIONAHA.104.476903>.
- Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Takada S, Kadoguchi T, Oba K, Okita K and Tsutsui H** (2015) Serum brain-derived neurotrophic factor level predicts adverse clinical outcomes in patients with heart failure. *Journal of Cardiac Failure* **21**(4), 300–306. <https://doi.org/10.1016/j.cardfail.2015.01.003>.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators** (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1789–1858.
- Han W, Zhang C, Wang H, Yang M, Guo Y, Li G, Zhang H, Wang C, Chen D and Geng C, Jiang P** (2019) Alterations of irisin, arpin, preptin and BDNF concentrations in coronary heart disease patients comorbid with depression. *Annals of Translational Medicine* **7**(14), 298.
- Hashimoto K** (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. *Progress in Neurobiology* **100**, 15–29.
- Hellweg R, von Arnim CAF, Büchner M, Huber R and Riepe MW** (2003) Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation. *Experimental Neurology* **183**(2), 346–354.
- Holmes DR, Selzer F, Johnston JM, Kelsey SF, Holubkov R, Cohen HA, Williams DO and Detre KM** (2003) National Heart, Lung, and Blood Institute Dynamic Registry, 2003. Modeling and risk prediction in the current era of interventional cardiology: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. *Circulation* **107**(14), 1871–1876. <https://doi.org/10.1161/01.CIR.0000065229.72905.78>.
- Jiang H, Liu Y, Zhang Y and Chen ZY** (2011) Association of plasma brain-derived neurotrophic factor and cardiovascular risk factors and prognosis in angina pectoris. *Biochemical and Biophysical Research Communications* **415**(1), 99–103. <https://doi.org/10.1016/j.bbrc.2011.10.020>.
- Kadowaki S, Shishido T, Honda Y, Narumi T, Otaki Y, Kinoshita D, Nishiyama S, Takahashi H, Arimoto T, Miyamoto T, Watanabe T and Kubota I** (2016) Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome. *Heart Vessels* **31**(4), 535–544. <https://doi.org/10.1007/s00380-015-0628-6>.
- Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, Jeong MH, Yoon JS and Kim JM** (2016). BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome. *Journal of Affective Disorders* **194**, 1–8. <https://doi.org/10.1016/j.jad.2016.01.033>.
- Kermani P, Rafii D, Jin DK, Whitlock P, Schaffer W, Chiang A, Vincent L, Friedrich M, Shido K, Hackett NR, Crystal RG, Rafii S and Hempstead, BL** (2005). Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. *The Journal of Clinical Investigation* **115**(3), 653–663. <https://doi.org/10.1172/JCI200522655>.
- Kroenke K, Spitzer RL and Williams JB** (2001) The PHQ-9: Validity of a Brief Depression Severity Measure. *Journal of General Internal Medicine* **16**(9), 606.
- Kuhlmann SL, Tschorn M, Arolt V, Beer K, Brandt J, Grosse L, Haverkamp W, Müller-Nordhorn, J, Rieckmann N, Waltenberger J, Warnke K, Hellweg R and Ströhle A** (2017) Serum brain-derived neurotrophic factor and stability of depressive symptoms in coronary heart disease patients: A prospective study. *Psychoneuroendocrinology* **77**, 196–202. <https://doi.org/10.1016/j.psyneuen.2016.12.015>.
- Lespérance F, Frasere-Smith N, Talajic M and Bourassa MG** (2002) Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. *Circulation* **105**(9), 1049–1053.
- Lewis M and Kuerbis A** (2016) An overview of causal directed acyclic graphs for substance abuse researchers. *Journal of Drug and Alcohol Research* **5**(1), 1–8.
- Liu YQ, Su GB, Duan CH, Wang JH, Liu HM, Feng N, Wang QX, Liu XE and Zhang J** (2014) Brain-derived neurotrophic factor gene polymorphisms are associated with coronary artery disease-related depression and antidepressant response. *Molecular Medicine Reports* **10**(6), 3247–3253. <https://doi.org/10.3892/mmr.2014.2638>.
- Manni L, Nikolova V, Vyagova D, Chaldakov GN and Aloe L** (2005) Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. *International Journal of Cardiology* **102**(1), 169–171. <https://doi.org/10.1016/j.ijcard.2004.10.041>.
- Mbakwem A, Aina F and Amadi C** (2016) Expert opinion—depression in patients with heart failure: Is enough being done? *Cardiac Failure Review* **2**(2), 110–112. <https://doi.org/10.15420/cfr.2016.21.1>.
- Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP and de Jonge P** (2011) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. *General Hospital Psychiatry* **33**(3), 203–216. <https://doi.org/10.1016/j.genhosppsych.2011.02.007>.
- Molendijk ML, Spinhoven P, Polak M, Bus BAA, Penninx BWJH and Elzinga BM** (2014) Serum BDNF concentrations as peripheral manifestations of depression: Evidence from a systematic review and meta-analyses on 179 associations (N=9484). *Molecular Psychiatry* **19**(7), 791–800. <https://doi.org/10.1038/mp.2013.105>.
- Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I, Nojima A, Ito T, Yoshida Y, Kobayashi Y, Katagiri H, Minamino T and Komuro I** (2012) Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway. *Arteriosclerosis, Thrombosis, and Vascular Biology* **32**(8), 1902–1909. <https://doi.org/10.1161/ATVBAHA.112.248930>.
- Pius-Sadowska E and Machaliński B** (2017) BDNF - A key player in cardiovascular system. *Journal of Molecular and Cellular Cardiology* **110**, 54–60. <https://doi.org/10.1016/j.yjmcc.2017.07.007>.
- Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG and Tongiorgi E** (2015) A method for reproducible measurements of serum BDNF: Comparison of the performance of six commercial assays. *Scientific Reports* **5**, 17989. <https://doi.org/10.1038/Srep17989>.
- Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, Secher NH, Pedersen BK and Pilgaard H** (2009). Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. *Experimental Physiology* **94**(10), 1062–1069.
- Rehm J and Shield KD** (2019) Global burden of disease and the impact of mental and addictive disorders. *Current Psychiatry Reports* **21**(2), 10.
- Rudisch B and Nemeroff CB** (2003) Epidemiology of comorbid coronary artery disease and depression. *Biological Psychiatry* **54**(3), 227–240.
- Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H and Gass P** (2009). Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. *Pharmacopsychiatry* **42**(06), 270–276. <https://doi.org/10.1055/s-0029-1224162>.

- Schmalhofer ML, Markus MR, Gras JC, Kopp J, Janowitz D, Grabe HJ, Groß S, Ewert R, Gläser S, Albrecht D, Eiffler I, Völzke H, Friedrich N, Nauck M, Steveling A, Könemann S, Wenzel K, Felix SB, Dörr M and Bahls M (2019) Sex-Specific associations of brain-derived neurotrophic factor and cardiorespiratory fitness in the general population. *Biomolecules* 9(10), 630.
- Serra-Millàs M (2016) Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? *World Journal of Psychiatry* 6(1), 84–101. <https://doi.org/10.5498/wjp.v6.i1.84>.
- Shrier I and Platt RW (2008) Reducing bias through directed acyclic graphs. *BMC Medical Research Methodology* 8(1), 70.
- Siew ED, Peterson JF, Eden SK, Moons KG, Ikizler TA and Matheny ME (2013) Use of multiple imputation method to improve estimation of missing baseline serum creatinine in acute kidney injury research. *Clinical Journal of the American Society of Nephrology* 8(1), 10–18. <https://doi.org/10.2215/CJN.00200112>.
- Smolderen KG, Spertus JA, Reid KJ, Buchanan DM, Krumholz HM, Denollet J, Vaccarino V and Chan PS (2009) The association of cognitive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes* 2(4), 328–337. <https://doi.org/10.1161/CIRCOUTCOMES.109.868588>.
- Takashio S, Sugiyama S, Yamamuro M, Takahama H, Hayashi T, Sugano Y, Izumiya Y, Hokimoto S, Minamino N, Yasuda S, Anzai T and Ogawa H (2015) Significance of low plasma levels of brain-derived neurotrophic factor in patients with heart failure. *The American Journal of Cardiology* 116(2), 243–249. <https://doi.org/10.1016/j.amjcard.2015.04.018>.
- Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar S and Knudsen GM (2007) Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. *Brain Research Bulletin* 73(1–3), 143–149.
- Tschorn M, Rieckmann N, Arolt V, Beer K, Haverkamp W, Martus P, Waltenberger J, Müller-Nordhorn J and Ströhle A (2019) Diagnostic accuracy of German depression screenings in patients with coronary heart disease. *Psychiatrische Praxis* 46(1), 41–48. <https://doi.org/10.1055/s-0042-123434>.
- Wang SY, Freeman MR, Sathish V, Thompson MA, Pabelick CM and Prakash YS (2016) Sex steroids influence brain-derived neurotrophic factor secretion from human airway smooth muscle cells. *Journal of Cellular Physiology* 231(7), 1586–1592.
- Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB and Browner WS (2008) Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. *JAMA* 300(20), 2379–2388.
- Williams TC, Bach CC, Matthiesen NB, Henriksen TB and Gagliardi L (2018) Directed acyclic graphs: a tool for causal studies in paediatrics. *Pediatric Research* 84(4), 487–493.
- Zhang XB, Wang X, Sha WW, Zhou HH and Zhang YM (2011) Val66Met polymorphism and serum brain-derived neurotrophic factor concentration in depressed patients. *Acta Neuropsychiatrica* 23(5), 229–234.
- Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, Lang UE, Steinhagen-Thiessen E, Schaub RT and Hellweg R (2007) Serum neurotrophins—a study on the time course and influencing factors in a large old age sample. *Neurobiology of Aging* 28(9), 1436–1445. <https://doi.org/10.1016/j.neurobiolaging.2006.06.011>.